{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:31:10Z","timestamp":1762252270485},"reference-count":36,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,22]]},"DOI":"10.18632\/oncotarget.4611","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T16:51:29Z","timestamp":1443459089000},"page":"25217-25225","source":"Crossref","is-referenced-by-count":17,"title":["Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes I\u03baB\u03b1 mediated p53 nuclear exclusion"],"prefix":"10.18632","volume":"6","author":[{"given":"Sabrina","family":"Crivellaro","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Panuzzo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Carr\u00e0","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Volpengo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Crasto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Gottardi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ubaldo","family":"Familiari","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Oncology, University of Turin at St Luigi Hospital, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Papotti","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Oncology, University of Turin at St Luigi Hospital, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Torti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milano-Bicocca, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Redaelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milano-Bicocca, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Taulli","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Guerrasio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Morotti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,7,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"476","author":"Pandolfi","year":"2011","journal-title":"Nature"},{"key":"3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tips.2010.12.005","article-title":"Non-genomic loss of PTEN function in cancer: not in my genes","volume":"32","author":"Foti","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"4","first-page":"216","article-title":"The multiple layers of non-genetic regulation of PTEN tumour suppressor activity","volume":"50","author":"Barata","year":"2014","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1196\/annals.1322.050","article-title":"Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia","volume":"1028","author":"Volpe","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14712598.2014.867323","article-title":"Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia","volume":"14","author":"Saglio","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"9","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Melo","year":"2015","journal-title":"Ann Hematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/stem.1678","article-title":"Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting","volume":"32","author":"Holyoake","year":"2014","journal-title":"Stem Cells Dayt Ohio"},{"key":"11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Barnes","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Quackenbush","year":"1998","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Ellis","year":"2013","journal-title":"J Clin Invest"},{"key":"14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Rosmarin","year":"2010","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/leu.2013.370","article-title":"BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP","volume":"28","author":"Berger","year":"2014","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/15384101.2015.1006970","article-title":"BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation","volume":"14","author":"Guerrasio","year":"2015","journal-title":"Cell Cycle Georget Tex"},{"key":"17","doi-asserted-by":"crossref","first-page":"e110682","DOI":"10.1371\/journal.pone.0110682","article-title":"BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia","volume":"9","author":"Morotti","year":"2014","journal-title":"PloS One"},{"key":"18","doi-asserted-by":"crossref","first-page":"e88298","DOI":"10.1371\/journal.pone.0088298","article-title":"PTEN regulates BCRP\/ABCG2 and the side population through the PI3K\/Akt pathway in chronic myeloid leukemia","volume":"9","author":"Zeng","year":"2014","journal-title":"PloS One"},{"key":"19","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Ceccon","year":"2012","journal-title":"Am J Hematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/MCB.22.4.1060-1072.2002","article-title":"Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis","volume":"22","author":"Ponzetto","year":"2002","journal-title":"Mol Cell Biol"},{"key":"21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-\u03baB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/cncr.20182","article-title":"Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies","volume":"100","author":"Giles","year":"2004","journal-title":"Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation","volume":"12","author":"Baldwin","year":"1998","journal-title":"Genes Dev"},{"key":"24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaB\/Rel activation","volume":"31","author":"Munzert","year":"2003","journal-title":"Exp Hematol"},{"key":"25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.20732","article-title":"NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line","volume":"81","author":"Defilippi","year":"2006","journal-title":"Am J Hematol"},{"key":"26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2403998","article-title":"The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance","volume":"20","author":"Messa","year":"2006","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","article-title":"IKK-dependent activation of NF-\u03baB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1","volume":"123","author":"Van Etten","year":"2014","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Bhatia","year":"2013","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.24294","article-title":"NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants","volume":"125","author":"Cassuto","year":"2009","journal-title":"Int J Cancer J Int Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"10323","DOI":"10.1074\/jbc.M106607200","article-title":"The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression","volume":"277","author":"Chang","year":"2002","journal-title":"J Biol Chem"},{"key":"31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2172-6-12","article-title":"Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors","volume":"6","author":"Ghoda","year":"2005","journal-title":"BMC Immunol"},{"key":"32","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.3748\/wjg.v12.i41.6658","article-title":"Effects of IkappaBalpha and its mutants on NF-kappaB and p53 signaling pathways","volume":"12","author":"Chen","year":"2006","journal-title":"World J Gastroenterol WJG"},{"key":"33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Attardi","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Rotter","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Perrotti","year":"2004","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CCO.0b013e32835b639e","article-title":"p21WAF1 and tumourigenesis: 20 years after","volume":"25","author":"El-Deiry","year":"2013","journal-title":"Curr Opin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T14:10:09Z","timestamp":1589379009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,23]]},"references-count":36,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2015,9,22]]}},"alternative-id":["4611","26295305"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4611","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,23]]}}}